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Abstract: Malignant gliomas are the most common and aggressive form of brain tumors. 
Current therapy consists of surgical resection, followed by radiation therapy and concomitant 
chemotherapy. Despite these treatments, the prognosis for patients is poor. As such, investiga-
tive therapies including tumor vaccines have targeted this devastating condition. Recent clinical 
trials involving immunotherapy, speciﬁ  cally dendritic cell (DC) based vaccines, have shown 
promising results. Overall, these vaccines are well tolerated with few documented side effects. 
In many patients receiving vaccines, tumor progression was delayed and the median overall 
survival of these patients was prolonged. Despite these encouraging results, several factors have 
limited the efﬁ  cacy of DC vaccines. Here we discuss the potential of DC vaccines as adjuvant 
therapy and current obstacles of generating highly pure and potent DC vaccines in the context 
of malignant glioma. Taken together, the results from earlier clinical studies justify additional 
clinical trials aimed at improving the efﬁ  cacy of DC vaccines.
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Introduction
Brain tumors are a diverse group of biologically and pathologically distinct intracranial 
neoplasms that include tumors of neuroepithelial tissue (gliomas), meningeal tumors, 
and primary lymphomas of the central nervous system (non-gliomas) (See Buckner 
et al 2007 for review). Gliomas typically arise from two different cell types in the brain, 
astrocytes or oligodendrocytes. The most common primary malignant astrocytoma 
is grade IV (World Health Organization, WHO) malignant glioma or glioblastoma 
multiforme (GBM). GBM is a highly invasive and aggressive tumor that responds 
poorly to therapy. Current therapy begins with surgical resection, followed by radiation 
therapy with concurrent chemotherapy. The median overall survival for these patients 
is 14.6 months with a 2-year survival rate of 26.5% (Stupp et al 2005), although the 
prognosis is much poorer for those patients whose tumor was not completely resected 
(Yuile et al 2006). As such, novel treatments are desperately needed to improve the 
outcome for patients with GBM. Recently, several Phase I clinical trials involving 
immunotherapy of malignant gliomas have shown promising results (Yu et al 2001; 
Yamanaka et al 2003; Caruso et al 2004; Kikuchi et al 2004; Rutkowski et al 2004; 
Steiner et al 2004; Yu et al 2004; Liau et al 2005; Yajima et al 2005; Yamanaka et al 
2005). Most of these trials have enrolled patients with grade III anaplastic astrocytoma 
and/or grade IV GBM and have used the antigen presenting cell known as a dendritic 
cell (DC) as the foundation of these vaccines. In this review we will focus on the safety 
and efﬁ  cacy experience to date of DC based vaccines for the treatment of malignant 
gliomas.
Evidence for anti-glioma immunity
Malignant gliomas have not generally been considered an appropriate target for 
immunotherapy. Malignant gliomas produce an immunosuppressive environment Biologics: Targets & Therapy 2008:2(4) 754
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through multiple mechanisms. GBMs secrete a variety 
of immunosuppressive cytokines including IL-10, VEGF, 
and TGF-β (Gomez and Kruse 2006) that can inhibit 
CD8+ T cell function and stimulate T regulatory cells. 
Patients with GBM are often lymphopenic with particular 
deﬁ  ciencies in CD4+ cell numbers and function. Fecci et al 
reported that, although the peripheral blood CD4+ population 
is lower in GBM patients compared to normal individuals, 
the percentage of CD4+ CD25+ FOXP3+ CD45RO+ T 
regulatory cells (Tregs) is higher in GBM patients (Fecci et al 
2006). This study, coupled with another demonstrating that 
GBM tumors exhibit higher ratios of Tregs in tumor inﬁ  ltrat-
ing lymphocytes (El Andaloussi and Lesniak 2006), indicates 
that Tregs play an active role in GBM-mediated immunosup-
pression. Immunosuppressive cytokines secreted by gliomas 
may also adversely affect the function and phenotype of 
monocytes (Woiciechowsky et al 1998; Ogden et al 2006). 
Myeloid-derived suppressor cells have been shown to be 
involved in promoting tumor progression in animal models of 
glioma (Prins et al 2002; Graf et al 2005). These suppressor 
cells and/or immature myeloid cells impair immune function 
by the direct suppression of T cells and adversely affect the 
differentiation of monocytes to dendritic cells (Kusmartsev 
and Gabrilovich 2006). In agreement with animal models, 
data from our group and others demonstrate that monocytes 
isolated from glioblastoma patients were unable to fully 
differentiate into mature dendritic cells (Ogden et al 2006) 
(and our own unpublished data). Finally, the brain may physi-
cally obstruct immune based therapies as it is considered 
an immune privileged site due to the restrictive blood brain 
barrier. However, this perception is now changing as several 
studies demonstrate active interaction between leukocytes, 
their immune responses, and the blood brain barrier (Simpson 
et al 1998; Biernacki et al 2004; Ifergan et al 2008). For 
example, endothelial cells of the blood brain barrier actively 
secrete cytokines to recruit CD14+ monocytes and induce 
migration and differentiation across the barrier in inﬂ  amma-
tory conditions (Ifergan et al 2008). In this light, malignant 
gliomas may be substantially more susceptible to immune 
modulation than previously thought.
Over the past several years, there has been growing 
evidence that malignant gliomas are in fact susceptible to 
targeted stimulation of the immune system. For example, 
natural speciﬁ  c anti-glioma immunity has been observed 
in certain animal models (Fecci et al 2003) and in humans. 
In a study of peripheral blood of GBM patients, Tang et al 
observed glioma-speciﬁ  c T cell responses in newly diagnosed 
patients (Tang et al 2005). They observed CD8+ T cell 
speciﬁ  c targeting against autologous tumor tissue and an 
established GBM cell line but not from other tumor types. 
Ueda et al presented a case report of a patient who survived 
an anaplastic astrocytoma for twelve years. The population 
of peripheral CD8+ T cells in this patient had high ratios of 
CD45RA–/CCR7 + memory cells and CD45RA–/CCR7– late 
effector cells and could produce a CD8+ T cell immune 
response speciﬁ  c for two glioma-associated antigens, Eph2a 
and IL-13Rα2 (Ueda et al 2007). Finally, most human 
gliomas contain tumor inﬁ  ltrating lymphocytes and their 
presence may have some prognostic value (Bucciero et al 
1990). These results suggest that the immunogenicity of 
GBM in humans is sufﬁ  cient to induce a tumor speciﬁ  c 
immune response despite the heterogeneity and anatomic 
localization of these tumors.
Summary of clinical trials using 
vaccines for brain tumors
The anecdotal evidence of immune susceptibility of GBM 
has led to several early phase clinical trials evaluating the 
safety and feasibility of brain tumor vaccines (Yu et al 
2001; Kikuchi et al 2002; Yamanaka et al 2003; Caruso 
et al 2004; Rutkowski et al 2004; Steiner et al 2004; Yu et al 
2004; Liau et al 2005; Yajima et al 2005; Yamanaka et al 
2005) (Table 1). While most investigators have focused on 
DC based therapies, others have chosen immunization with 
other modalities such as free peptides, genetically-modiﬁ  ed 
tumor cells, or expanded autologous T-cells. Differences in 
antigen and vaccine strategies make comparisons difﬁ  cult, 
however, several observations can be made in examining 
the trials in aggregate. A major concern in immunotherapy 
is the induction of autoimmune responses within the central 
nervous system, a potentially devastating side effect. As such, 
most trials pay particular attention to the induction of autoim-
munity. Signiﬁ  cantly, no trial has yet reported any evidence 
of the consistent induction of adverse autoimmunity. The 
lack of autoimmunity has been accompanied by an overall 
impressive safety proﬁ  le with only one Grade 3 or Grade 4 
adverse event reported. This patient suffered from peritumoral 
edema after the second vaccination subsequently controlled 
by the administration of steroids (Rutkowski et al 2004). 
The most common reported side effects included fevers, 
headaches, nausea, and mild erythema and/or induration at 
the site of injection.
The clinical response to vaccines has varied substantially 
across all reported trials (Table 1). While every trial reported 
evidence of clinical responses in some patients, the nature and 
duration of the response to the vaccines varied signiﬁ  cantly. Biologics: Targets & Therapy 2008:2(4) 755
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Of the ﬁ  ve trials reporting survival data, each of the patient 
groups receiving vaccines had a prolonged overall median 
survival (an average of the trials of about a 2.5-fold increase) 
or a higher percentage surviving at 2 years (Yu et al 2001; 
Steiner et al 2004; Yu et al 2004; Liau et al 2005; Yamanaka 
et al 2005). In addition, two of the trials report that some 
patients were in complete remission beyond the end of the 
study (Rutkowski et al 2004; Liau et al 2005). Interestingly, 
many of the investigators reported that they were not always 
able to correlate overall survival to the cellular immune 
responses observed in the patient. The data from these tri-
als also indicate that there may be a sub-population of patients 
who will respond well to these vaccines. Overall, the trials 
have documented a favorable safety proﬁ  le and in some cases 
Table 1 Summary of clinical trials using vaccines as therapy for malignant gliomas
Clinical 
trial
Trial 
stage
Cohorta Antigen 
sourceb
Adjuvantc Dose Frequency # of 
vaccines
Routed Safetye Immune 
outcomesf
Clinical 
outcomesg
Yu et al Phase I N = 9 Mixed, 
ND
Peptides 
derived 
from ACTC
IDC 106 DC 2 wks 3 s.c. ++ ISR, CTL, 
TIL
MS:455 days 
vs 257 days
Steiner 
et al
Pilot 
Study
N = 23 
GBM, ND?
ACTC Newcastle 
disease 
virus
107 Tumor 
cells
1st 4:3 wks 
2nd 4:4 wks
8 i.d. ++ ISR, DTH, 
CTL, TIL
MS:100 
vs 49 wks
Yamanaka 
et al
Phase I/II N = 10 
Mixed, 
recurrent
ATL IDC + KLH 10–32 × 106 
DC
3 wks Up to 10 i.d.or i.t. ++ ISR, DTH, 
CTL, TIL
2 PR
Rutkowski 
et al
Phase I N = 12 
Mixed, 
recurrent
ATL MDC 2–4 × 106 
DC
1 wk
2 wks
4 wks
2–7 i.d. ++ DTH 2 CCR 2 PR 
or SD
Yu et al Phase I N = 14 
Mixed, both
ATL IDC 107–108 DC 2 wks 3 s.c. ++ ISR, CTL, 
TIL
MS:133 wks 
vs 30 wks
Caruso 
et al
Phase I N = 9 Mixed, 
recurrent
Primary 
tumor RNA
IDC 0.5 × 107 
DC (i.d.) 
0.5–5 × 107 
DC (i.v.)
Bi-wk 6 i.d. and 
i.v.
++ No CTL 
observed
2 SD 1 PR
Kikuchi 
et al
Phase I N = 15 
Mixed, 
recurrent
ACTC MDC+ 
IL-12
3.6–32.3 ×
106 Fused 
Tumor 
Cell/DC
2 wks Up to 6 i.d. ++ ISR, CTL, 
TIL
4 PR
Liau et al Phase I N = 24 GBM, 
both
Peptides 
derived 
from ACTC
IDC 1,5, or 
10 × 106 
DC
Bi-wk 3 i.d. ++ ISR, CTL, 
TIL
MS:35.8 mo. 
vs 18.3 mo. 
1 near CR
Yamanaka 
et al
Phase I/II N = 24 
Mixed, 
recurrent
ATL MDC+ 
KLH or 
OK-432
1–32 × 106 
DC
3 wks Up to 10 i.d. or 
i.t.
++ ISR, DTH, 
CTL
Survival:
23.5% at 
2 yrs. vs 3.7%
Yajima 
et al
Phase I N = 25 
Mixed, both
Manufact-
ured 
peptides
Monatanide 
ISA 51
3 mg/ml 
peptides + 
adjuvant
Wk or 
Bi-wk
Up to 
24?
s.c. ++ ISR, DTH, 
CTL
5 PR 8 SD 
8 PD
aClinical trials involved patients with malignant glioma (grade III anaplastic astrocytoma or grade IV glioblastoma multiforme (GBM) or both (mixed)) and were newly diagnosed 
(ND) or had recurrent disease. Caruso et al enrolled pediatric patients with various brain tumors.
bACTC, autologous cultured tumor cells; ATL, autologous tumor lysates.
cMost studies involved immature (IDC) or mature (MDC) dendritic cells. Most DC culture conditions involved a 7 day culture system of adherent PBMCs with medium 
containing 10% fetal calf serum or 1%–10% autologous human serum plus GM-CSF and IL-4. When MDCs were used, methods were consistent with possible DC maturation 
but not reported on every patient.
di.d, intra-dermal; i.t, intra-tumor; i.v, intra-venous; s.c, sub-cutaneous.
e++ indicates no grade III or grade IV adverse events or no evidence of autoimmunity. Rutkowski et al report 1 patient having Grade IV neurological deﬁ  cits resulting from 
peri-tumoral edema.
fReported observations include ISR, injection site reaction (induration, erythema); DTH, delayed type hypersensitivity; CTL, cytotoxic T lymphocyte (evidence of speciﬁ  c anti-
tumor T cell responses); TILs, tumor inﬁ  ltrating lymphocytes (conﬁ  rmed presence).
gMS, median overall survival; PR, partial response; CCR, complete continous response; SD, stable disease; PD, progressive disease; CR complete response.Biologics: Targets & Therapy 2008:2(4) 756
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improved survival, however, no correlative biomarker or 
immune function has predicted clinical responses.
Obstacles to optimal GBM vaccine 
efﬁ  cacy
Beyond the shared characteristics of these trials, there exists 
a lack of consensus of many aspects of this approach. There 
is a signiﬁ  cant need for standardization of vaccine prepara-
tions to collectively improve therapeutic response. Here, 
we will discuss several aspects of vaccine development that 
need more focused attention in order to improve the potency 
of this approach. Since most trials use DCs as an adjuvant 
for vaccines, we will speciﬁ  cally focus on issues relating to 
DC-based vaccines.
Dendritic cell culture
The primary goal of immunotherapy is the induction of 
anti-tumor immunity while minimizing autoimmunity. The 
appropriate activation of naïve and memory T cells, NK and 
NKT cells are essential to directing a beneﬁ  cial anti-tumor 
immune response. The cells most capable of activating these 
and other immune effector cells are DCs (for review see 
O’Neill et al 2004; Panoskaltsis et al 2004). DCs arise from 
both lymphoid and myeloid progenitors within the bone 
marrow. CD14+ monocytes can give rise to immature DCs 
as they migrate from the blood stream to peripheral tissues 
(Pickl et al 1996). Immature DC are characterized by their 
ability to induce a tolerizing immune phenotype through 
activation of regulatory T cells, and inability to stimulate 
naïve or antigen speciﬁ  c memory T cells (Dhodapkar and 
Steinman 2002; Wakkach et al 2003). In the peripheral tissues, 
immature DCs sample their environment via phagocytosis 
and macropinocytosis. The presence of toll-like receptor 
(TLR) ligands provided by microorganisms or stimulating 
cytokines induces a transformation into fully activated mature 
DCs, with resulting presentation of the internalized entities 
on appropriate MHC molecules. Mature DCs express high 
levels of Class I and Class II molecules, altered chemokine and 
galectin family (Dietz et al 2000; Bax et al 2007) expression, 
co-stimulatory markers CD80 and CD86, and the immu-
noglobulin CD83 (Zhou and Tedder 1995). They migrate 
to draining lymph nodes and activate innate and adaptive 
immune responses. To stimulate a similar response in brain 
cancer patients, DC progenitors (usually monocytes) are 
cultured to generate DC and pulsed with proteins associated 
with tumors to generate an anti-tumor immune response.
Two methods are currently being investigated to develop 
antigen-loaded and fully activated DCs. One method is to 
target DCs in vivo by targeting antigens to DC cell surface 
receptors such as the mannose receptor, CD205, or DC-SIGN 
(see Tacken et al for review (Tacken et al 2007)). After 
antigens are administered, DC maturation signals like TLR 
ligands, activators of CD40, or α-galactosylceramide are 
then given systemically (Fujii et al 2003; Bonifaz et al 2004; 
van Duin et al 2006; Lapteva et al 2007). The other method 
involves ex vivo culture of DCs where antigens are loaded 
and DCs are matured in the culture dish before administra-
tion. While each method has its own advantages, the scarcity 
of DC in vivo and the difﬁ  culty in targeting and activation 
limit the capacity for in vivo targeting whereas the ability 
to isolate and differentiate CD14+ monocytes to DCs from 
whole blood provides an abundant source of DCs (Pickl et al 
1996; Zhou and Tedder 1996). Therefore, most clinical trials 
manipulate DC through ex vivo culture to assure accurate 
antigen delivery and DC activation.
Most culture systems used in clinical trials have been 
adapted from the standard 10-day culture method of 
adherent peripheral blood mononuclear cells in a base media 
containing serum, either fetal calf serum or autologous human 
serum, with the addition of GM-CSF and IL-4 (Sallusto and 
Lanzavecchia 1994; Kiertscher and Roth 1996; Jonuleit et al 
1997). DCs are recovered, incubated with antigen, and then 
aliquoted for individual doses. If the DCs are not cultured 
in additional inﬂ  ammatory cytokines or toll-like receptor 
ligands, the method results in immature DCs. While antigen 
uptake is enhanced in immature DCs, they can to induce 
tolerance if not fully activated (Steinman and Nussenzweig 
2002). For example, in vivo injection of immature DCs 
loaded with inﬂ  uenza matrix peptide led to antigen speciﬁ  c 
silencing of effector cells (Dhodapkar and Steinman 2002). 
Also, in a study involving patients with stage IV melanoma, 
de Vries et al directly compared the efﬁ  cacy vaccines using 
immature or mature DCs in inducing an immune response 
(de Vries et al 2003). They reported that delayed-type hyper-
sensitivity reactions and humoral responses to KLH were 
observed in patients receiving mature DCs whereas those 
receiving immature DCs had no DTH reactions and few KLH 
responses. These responses correlated with improved clinical 
outcomes for patients receiving mature DCs (de Vries et al 
2003). Five of the eight GBM clinical trials that used DC vac-
cines administered immature DCs (see Table 1, Adjuvants). 
The other three trials included maturation stimuli in their 
culturing methods. Since only fully activated, mature DCs 
are able to migrate to lymph nodes and optimally promotes 
T cell activation, culturing mature DCs should strongly be 
encouraged for clinical trial use.Biologics: Targets & Therapy 2008:2(4) 757
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Unfortunately, there is significant variability in the 
reporting of the phenotype of DCs used for vaccines. 
We agree with Figdor et al (2004) that as part of the 
standardization and release criteria for DC vaccines, full DC 
phenotypes should be reported for each patient. For example, 
when monocyte-derived mature DCs are administered, the 
expression of maturation markers like CD83, CD80, and 
CD86 should be measured. With this information, the purity 
and potency of DC for each individual can be assessed to 
ensure the reproducible quality of the vaccine. Such proper-
ties may be useful in understanding the immunogenicity and 
clinical efﬁ  cacy.
Due to the variety of culturing conditions in the reported 
trials, standardized protocols to reliably manufacture mature 
DCs are necessary for future clinical trials. This protocol 
must be able to yield reproducible results and satisfy any 
regulatory guidelines that restrict, or in some cases disallow, 
governing the use of reagents for DC culture. Moreover, it 
is becoming recognized that a patient’s disease status may 
impact the outcome of culturing patient-derived monocytes. 
For example, Ogden et al report that monocytes isolated 
from GBM patients are phenotypically abnormal and have an 
impaired ability to differentiate into DCs (Ogden et al 2006). 
In agreement with this report, recent data from our laboratory 
indicate that cultured monocytes isolated from GBM patients 
are resistant to DC culture using classical protocols and result 
in mixed populations of immature and mature DC (Dietz 
unpublished data). We found that DC maturation is highly 
dependent on individual donors, base media and culture 
conditions, and the disease status of patient sub-groups. While 
CD80 expression was consistent in each culture condition, 
CD83 expression was much more sensitive to the differing 
conditions. CD83 is likely an important cell surface marker 
for mature DCs because it behaves like a co-stimulatory 
signal by priming naïve CD8+ T cells, induces their antigen-
speciﬁ  c expansion and prolongs their survival (Hirano et al 
2006; Aerts-Toegaert et al 2007). In summary, improvements 
to DC vaccines is a critical step toward the optimization of 
vaccine strategies for GBM and further improvement to these 
vaccines will require close attention and reporting of the DC 
phenotypes used in the vaccine.
Antigen source and delivery
For cancer vaccines to be effective, the source of tumor 
antigen must also be carefully considered. Autologous 
tumor tissue, cultured tumor cells, whole tumor RNA, 
and tumor peptides have all been used as antigen sources. 
Primary tumor lysates or whole tumor RNA generated by 
processing resected tumors are the most common antigen 
sources and offer the advantage of providing multiple 
tumor antigens. However, tumor protein lysates and RNA 
present three problems: (1) lysates or RNA made from 
tumor tissue are often in limited quantities; (2) they are an 
inconsistent source of antigenic material and can make 
immune monitoring problematic and (3) they may often be 
contaminated with non-target cells such as normal brain, 
endothelium, or cells of hematopoetic origin. Alternatively, 
tumor cells may be cultured to expand the amount of antigen 
source and reduce the amount of contaminating material. 
While most researchers have used media supplemented with 
ten percent fetal calf serum, recent evidence suggests that 
GBM cells cultured in this method are phenotypically and 
biologically different than the primary tumor from which they 
are derived (Lee et al 2006). However, GBM cells grown 
in serum-free medium supplemented with neurotrophic 
factors, and EGF and FGF, grow as ball-shaped structures 
called neurospheres, and maintain vital characteristics of the 
primary tumor, including gene expression proﬁ  les, tumori-
genicity, and genetic abnormalities (Lee et al 2006; de Witt 
Hamer et al 2008). In addition, these neurospheres contain 
a higher density of tumor stem cells that may elicit a better 
immune response in vivo than cells grown as a monolayer 
in serum containing medium possibly due to an increase in 
expression of MHC Class II molecules and/or co-stimulatory 
molecules (Pellegatta et al 2006). Additionally, by direct 
targeting of tumor stem cells, the vaccine might eradicate 
cells most critical to the proliferation and invasion of the 
tumor. The observations in these studies and in others 
highlight the importance of appropriate cell culture systems 
and that these systems should be carefully developed to 
optimally reﬂ  ect the phenotype and biology of the cells in 
vivo (Debnath et al 2003; Zhang et al 2005; Gustafson et al 
2006). While culturing tumor cells can be advantageous 
over the use of the primary tumor as an antigen, it may not 
be practical because of the time needed to generate enough 
cells for a vaccine or lack of clinical grade reagents needed 
for culturing. As culturing systems become more advanced, 
cultured tumor cells may provide sufﬁ  cient material, enriched 
for tumor antigens, and contain less contaminating material 
thereby making them a suitable antigen source for future 
vaccine trials.
Deﬁ  ned tumor associated antigens (TAA), whether it be 
in the form of peptides, RNA, or DNA provide convenience 
of using “off the shelf” reagents and allow for immune moni-
toring of speciﬁ  c TAAs. However, the potential of tumor 
antigen escape and the limited repertoire of using deﬁ  ned Biologics: Targets & Therapy 2008:2(4) 758
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antigens create inherent problems of their own. Peptides 
have additional problems because they are human leukocyte 
antigen (HLA) class I or II restricted, and consequently, 
restrict patient enrollment into clinical trials, and class I pep-
tides are insufﬁ  cient to generate a CD4+ T helper response 
which are required for optimal orchestration of effective and 
sustained anti-tumor immunity (Knutson and Disis 2005).
The optimal method for antigen delivery to DC is still 
controversial. However, a manuscript identifying the current 
consensus regarding an optimal antigen source concluded; 
“the most constitutive and prolonged MHC I presenta-
tion would likely result from processing of endogenously 
produced proteins located in the cytoplasm; like other cells, 
DC present self- or virus-derived endogenous antigens 
generated via proteasome degradation of newly synthesized 
ubiquitinated proteins.” (Katoh et al 2003) These expres-
sion characteristics limit the methods useful for delivering 
antigens to viral, DNA or RNA based delivery methods. Of 
these, RNA delivery of tumor-speciﬁ  c (TSA) and/or asso-
ciated antigens (TAA) has proven to be the most reliable, 
efﬁ  cient and stimulatory method available (Cabuy and de 
Ridder 2001; Liu et al 2004; Ozawa et al 2004).
In summary, there has been no consensus in the ﬁ  eld 
of DC vaccines for the optimal antigen source. Five of the 
10 trials listed in Table 1 (see Antigen Source column) use 
autologous tumor lysate or tumor-derived RNA, 3 trials used 
peptides (1 used manufactured peptides, and 2 derived from 
cultured cells), one trial used autologous tumor cells infected 
with a virus and one trial fused tumor cells to DCs. Four of the 
10 trials used culturing methods containing animal products 
(ie, fetal calf/bovine serum) in their culturing schemes. 
Animal serum has several disadvantages in clinical use 
including inconsistency between lots, potential introduction 
of adventitious organisms and alterations in the underlying 
biology of the tumor. Since the antigen source and delivery 
systems are crucial components in manufacturing an effec-
tive vaccine, the success of future clinical trials will require 
further research to address these concerns. Feasibility issues 
will also certainly need to be considered in the context of 
concurrent therapy for brain tumors.
DC vaccination as an adjuvant therapy
In the clinical setting, DC vaccines have essentially been 
used as adjuvant therapy after surgical resection of the 
embedded tumor. So far, it appears that the use of DC 
vaccines in the context of concurrent chemotherapy is 
feasible and has not resulted in additional toxicity. There 
are now reports demonstrating that appropriate timing of 
the vaccination can improve the outcome of GBM patients 
by either sensitizing tumor cells to further chemotherapy or 
synergize with chemotherapy to delay tumor progression 
and prolong survival (Wheeler et al 2004; Liu et al 2005). 
As such, DC vaccines could be used as an adjuvant therapy 
after surgical resection of the tumor. Further considerations 
are needed to determine whether there are optimal times of 
vaccination after surgery and to determine dosing schedules 
to best augment an anti-tumor response with current cycles 
of chemotherapy.
Patients receiving treatment for glioblastoma are often 
given steroids like dexamethasone or prednisone to treat 
tumor-associated edema. Dexamethasone is a widely used 
reagent that has well documented immunosuppressive capa-
bilities (Rhen and Cidlowski 2005). Dexamethasone has been 
shown to adversely affect the function of monocyte-derived 
DCs (Woiciechowsky et al 1998; van den Heuval et al 1999; 
Ogden et al 2006) and can enhance DCs mediated tolerance. 
In the context of malignant gliomas, some have reported 
that the presence of steroids may directly interfere with 
the vaccine itself (by reducing manufacturing efﬁ  ciency) 
(Rutkowski et al 2004) or that patients on steroids do not 
fare as well as those who are on little or no steroids (Yajima 
et al 2005). These observations highlight the need for further 
analysis of the effects of dexamethasone on immune func-
tion and anti-tumor immunity. For future clinical trials, the 
coordination of immunotherapy with steroid treatment and 
the impact of dexamethasone on the immune status of the 
patient are important additional factors to be considered.
Immune monitoring
Since tumor destruction is mediated secondarily to 
the generation of an immune response by the vaccines, 
immune monitoring has been a major component of prior 
GBM vaccine studies. Monitoring the biologic activity 
of the vaccine should be given as much emphasis as the 
clinical outcome, particularly if there is an interest in further 
vaccine optimization. However, immune monitoring remains 
a signiﬁ  cant challenge for a number of reasons. Foremost 
amongst these reasons are (1) signiﬁ  cant variability observed 
in in vitro functional T cell assays, (2) a lack of knowledge 
of what to measure, and (3) high costs in terms of labor and 
materials for assay development and validation (Knutson et al 
2006). The main goal of immune monitoring is to establish 
an immunologic correlate of clinical outcomes (Britten et al 
2008). These correlations have been elusive in all cancer 
settings and brain cancer vaccines are no exception. Of 
those trials discussed in this review, the best correlation was Biologics: Targets & Therapy 2008:2(4) 759
Brain tumor vaccines
described by Liau and colleagues, who showed that survival 
was positively correlated with the magnitude of T cell inﬁ  ltra-
tion into the tumors (Liau et al 2005). Despite that, it is clear 
that brain cancer vaccines are immunogenic and many of the 
patients enrolled in the clinical trials demonstrated elevated 
immune responses following vaccination.
The primary reason for the lack of correlations between 
the immune response to vaccine and clinical outcomes is that 
the trials are not adequately designed to detect these types of 
correlations. Rather, the trials are typically designed to test 
for feasibility and safety. Kielholz and colleagues recently 
published an outstanding treatise discussing the strengths 
and weaknesses of immune monitoring which included esti-
mates of sample sizes that are required to detect such clinical 
correlations. It is clear from their analysis that correlations 
between immunity and clinical responses (regressions and 
survival) are likely to only be borne out in advanced efﬁ  cacy 
trials rather than pilot, safety, and feasibility trials, where a 
considerably higher number of patients are enrolled (Keilholz 
et al 2006). Despite that, however, immune monitoring 
should be carefully developed in the early trials perhaps as 
recently delineated in a paradigm by the Cancer Vaccine 
Clinical Trial Working Group (CVCTWG) (Hoos et al 2007). 
This paradigm suggests that, given the acceptable safety 
proﬁ  les of cancer vaccines, early trials should be designed 
to test the feasibility that a candidate vaccine elicits either 
a biologic (ie, immune) or a clinical response in the target 
population. Once validated, these response assessments can 
then be correlated in future efﬁ  cacy trials.
Future directions and conclusions
The recent trials involving DC vaccination therapy for 
malignant gliomas have provided the groundwork in which 
future clinical trials can continue to improve. It is now 
encouraging to see that these trials are beginning to move 
to Phase II. For example, Dr Linda Liau, in conjunction with 
Northwest Biotherapeutics, Inc. (Seattle, WA), are currently 
enrolling patients with GBM for a multi-center Phase II 
to test the efﬁ  cacy of their autologous DC based vaccine, 
DCVax®-Brain (Northwest Biotherapeutics 2007). The target 
enrollment for the trial is 141 newly diagnosed patients. 
Patients will undergo surgery, radiation and concomitant 
chemotherapy. The primary endpoint for the trial is patient 
survival with no disease progression and the second endpoint 
is overall survival. This Phase II trial follows their ﬁ  rst trial 
in which GBM patients receiving the vaccine had a median 
survival of 35.8 months compared to 18.3 months for the 
control group with some patients surviving more than 
3 years with no evidence of tumor recurrence (Liau et al 
2005; Northwest Biotherapeutics 2007). The Phase II trial 
will add more vaccine doses (up to 10 over 2½ years) than 
the three doses given in the Phase I trial. The patient accrual 
is expected to end soon and the results of this trial will be 
highly anticipated.
Novel therapies are desperately needed for the treatment 
of malignant gliomas. Since DC vaccines have shown a very 
favorable safety proﬁ  le and that they are likely to work in 
conjunction with current therapeutic protocols, the prospects 
of using vaccines as a standard of care as adjuvant therapy 
looks promising. But until we can correlate patient immune 
responses to clinical outcomes, it is likely necessary to 
focus on six month progression free survival as the primary 
endpoint for clinical trials. As the obstacles to the efﬁ  ciency of 
DC vaccines are removed and the standardization of vaccines 
moves forward, these vaccines are likely to become a viable 
option for those patients facing difﬁ  cult treatments.
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